FDA TAP Pilot Program Guide: Total Product Life Cycle Advisory Strategy

Guide to FDA CDRH Total Product Life Cycle Advisory (TAP) Pilot Program, Breakthrough Device eligibility, 14-day advisor meetings, and CMS payor alignment.

Executive Summary & Direct Answer

The FDA CDRH Total Product Life Cycle Advisory Program (TAP) Pilot is an MDUFA V flagship initiative designed to de-risk medical device innovation by establishing early, rapid, and continuous engagement between medical device sponsors, dedicated FDA TAP Advisors, clinical experts, payors (including CMS), and patient advocates. Established under the Fifth Medical Device User Fee Amendments (MDUFA V) covering Fiscal Years 2023 through 2027, TAP fundamentally shifts regulatory interaction from a formal, static document submission model into a dynamic, consultative partnership.

For medical device sponsors holding an active FDA Breakthrough Device Designation (and select devices in the Safer Technologies Program, STEP), enrollment in TAP unlocks informal teleconferences scheduled within 14 calendar days of request and written advisor feedback within 40 calendar days—contrasting sharply with traditional Q-Submission (Pre-Sub) timelines that require 60 to 75 calendar days. Moreover, TAP is the only formal FDA program that proactively facilitates multi-stakeholder discussions, connecting sponsors directly with CMS reimbursement officers, commercial health plan medical directors, and professional society guideline committee members during early clinical trial protocol design.

This guide details TAP eligibility criteria across all seven CDRH Offices of Health Technology (OHT1 through OHT7), provides a granular operational comparison against standard Q-Submissions, analyzes MDUFA V enrollment capacity limits, examines real-world sponsor deployment scenarios, outlines dossier preparation rules, and details a step-by-step sponsor strategy for maximizing TAP ROI prior to pivotal clinical trial initiation.

What Is the FDA TAP Pilot Program and How Does It Differ From Q-Submissions?

Traditionally, medical device manufacturers interact with the FDA through the formal Q-Submission (Pre-Submission) program. While Q-Submissions allow sponsors to ask specific regulatory, non-clinical, and clinical questions, the process is structured as a series of isolated, transactional events. A sponsor submits a formal 50-to-100-page package, waits 60 to 75 days for a single 60-minute meeting, receives formal meeting minutes, and must submit an entirely new Q-Sub for follow-up questions.

The TAP Pilot Program was conceived under MDUFA V to break this transactional bottleneck. Rather than routing all communication through a branch chief or lead reviewer across rigid statutory review clocks, TAP assigns each enrolled device a dedicated TAP Advisor. The TAP Advisor functions as a regulatory and strategic concierge within CDRH, coordinating internal expert reviews and serving as a continuous point of contact throughout the device development lifecycle.

Traditional Q-Submission Track vs. FDA TAP Advisory Track

Traditional Q-Sub Track:
[Sponsor Drafts Q-Sub] ──(60-75 Days Wait)──► [Formal 60-Min Meeting] ──► [Minutes Issued]
       ▲                                                                         │
       └─────────────────── (New Q-Sub Required for Follow-up) ──────────────────┘

FDA TAP Advisory Track:
[TAP Enrollment] ──► [Dedicated TAP Advisor Assigned]
                          │
                          ├──► [14-Day Informal Teleconferences] (Ad-hoc / Frequent)
                          ├──► [40-Day Written Feedback Loops]
                          ├──► [Payor & CMS Coverage Alignment]
                          └──► [Patient & Clinical Society Engagement]

Key Differences: TAP vs. Standard Q-Sub vs. INTERACT vs. STEP

To help regulatory affairs leaders position TAP within their overall FDA submission strategy, the following matrix compares TAP against standard CDRH Q-Submissions, CBER INTERACT meetings, and the Safer Technologies Program (STEP):

Feature / Metric	FDA TAP Pilot Program	Standard Q-Submission (Pre-Sub)	CBER/CDRH INTERACT Meeting	Safer Technologies Program (STEP)
Primary Objective	Continuous, multi-stakeholder TPLC advisory	Formal FDA feedback on specific regulatory questions	Early informal guidance on novel early-stage concepts	Expedited review for non-Breakthrough safety innovations
Prerequisite Requirement	Active Breakthrough Device Designation (or select STEP)	None (open to all medical devices/IVDs)	Early development stage prior to Pre-Sub	Approved STEP Designation (Class II/III non-life-threatening)
Meeting Turnaround	Within 14 calendar days of request	60 to 75 calendar days from receipt	21 to 30 calendar days from request grant	Accelerated (tracked under MDUFA V Breakthrough metrics)
Written Feedback	Within 40 calendar days (informal touchpoints)	1 to 5 days prior to scheduled meeting	Included in final meeting summary	Priority written feedback on submission milestones
Interaction Frequency	Continuous / Multiple informal touchpoints	Transactional (one meeting per submission)	Single early-stage interaction	Periodic milestone-based interactions
Payor & CMS Engagement	Built-in / Proactive (CMS, private payors, coding)	Separate Payor Communication Taskforce request	Not available	Limited payor engagement focus
User Fee Cost	$0 (Funded under MDUFA V appropriation)	$0 (No MDUFA user fee for Q-Subs)	$0	$0

Sponsors preparing Breakthrough Device strategies should review the foundational requirements in our FDA Breakthrough Device Designation Guide and compare premarket submission timelines in our 510(k) Submission Guide.

Which Medical Devices Are Eligible for TAP Enrollment Across CDRH Offices (OHT1–OHT7)?

Enrollment in the TAP Pilot is subject to strict eligibility criteria established by FDA CDRH and agreed upon in the MDUFA V Commitment Letter. Not every medical device qualifies for TAP; enrollment is capped by fiscal year capacity and targeted specifically at high-impact medical technologies.

Mandatory Eligibility Criteria

To be considered for TAP enrollment, a medical device or in vitro diagnostic (IVD) must satisfy all of the following conditions:

Active Breakthrough Designation: The device must have received an official FDA Breakthrough Device Designation granted under Section 515B of the FD&C Act. Devices granted STEP status under the FDA Safer Technologies Program (STEP) may be considered in select expansion phases.
Early Development Stage: The device must be in early-stage development. FDA will reject TAP enrollment requests for devices that have already initiated pivotal clinical trials, submitted an Investigational Device Exemption (IDE), filed a marketing submission (510(k), De Novo, or PMA), or already filed a formal Pre-Submission (Q-Sub) request for FDA feedback after Breakthrough Designation or STeP acceptance was granted. This last restriction is the one sponsors most often miss: a single early Pre-Sub can disqualify a device from TAP, which is why enrollment must be requested immediately upon designation.
Participating CDRH Review Office: The device must fall under the jurisdiction of a CDRH Office of Health Technology (OHT) currently participating in the TAP rollout phase.
Available Fiscal Year Capacity: The enrollment request must be received before CDRH reaches its annual MDUFA V enrollment cap for that fiscal year.

CDRH OHT Expansion Schedule & Capacity Caps (FY 2023 – FY 2027)

MDUFA V set a phased enrollment plan so CDRH could recruit and train dedicated TAP Advisors without degrading core review performance. Per the MDUFA V commitment letter, the figures below are cumulative — each fiscal year carries forward the devices already enrolled, and the program adds a defined number of new devices each year:

Fiscal Year	Cumulative Enrollment Target (MDUFA V)	New Devices Added	Participating CDRH Offices of Health Technology (OHTs)
FY 2023	15 devices	15 (soft launch)	OHT2 — Office of Cardiovascular Devices only (soft launch began Jan 1, 2023)
FY 2024	60 devices	+45	OHT2 plus at least one additional OHT
FY 2025	125 devices	+65	At least four OHTs participating
FY 2026	225 devices	+100	Continued OHT expansion; STeP devices added; all-OHT enrollment opened July 1, 2026
FY 2027	325 devices	+100	All seven CDRH Offices of Health Technology (steady-state target)

Capacity targets versus actual enrollment. The MDUFA V figures above are commitment-letter capacity ceilings, not enrollment guarantees. The FY 2023 soft launch was deliberately small — up to 15 devices in OHT2 — because OHT2 carried the deepest pool of granted Breakthrough designations and the most experience with rapid-interaction programs such as Early Feasibility Studies. Public reporting indicates roughly 133 devices were enrolled as of July 1, 2026, below the FY 2026 cumulative capacity of 225, even as program reach extended across all seven OHTs after the July 1, 2026 expansion (which opened enrollment to Breakthrough-designated and Safer Technologies Program devices). Sponsors should treat the caps as an availability ceiling, not a guaranteed slot count, and request enrollment early.

MDUFA V Cumulative TAP Enrollment Target (Up to ~325 Devices by FY 2027)

  325 ┤                                                         ██ FY27 (+100)
      │                                                  ██████████
  225 ┤                                           ██ FY26 (+100)
      │                                    ██████████
  125 ┤                              ██ FY25 (+65)
      │                       ███████
   60 ┤                ██ FY24 (+45)
      │         █████
   15 ┤  ██ FY23 (+15, OHT2 soft launch)
      └────────────────────────────────────────────────────────────
         FY 2023   FY 2024   FY 2025   FY 2026   FY 2027

How Do TAP Advisor Interactions Work: Timelines, Meeting Structure, and Written Feedback

The operational centerpiece of the TAP Pilot is the TAP Advisor. TAP Advisors are senior CDRH personnel who possess deep expertise in medical device regulation, clinical trial design, biostatistics, and health economics. Unlike traditional CDRH lead reviewers who must balance primary review duties across dozens of active 510(k) or PMA files, TAP Advisors are dedicated full-time to advisory concierge functions.

Operational Timelines & Engagement Mechanisms

Once accepted into TAP, sponsors gain access to four rapid-response interaction mechanisms:

Informal Strategic Teleconferences (14 Calendar Days): Sponsors can request informal 30-to-45-minute teleconferences with their TAP Advisor to discuss emerging clinical data, protocol revisions, or non-clinical testing strategies. Meetings are scheduled within 14 calendar days of the request, eliminating month-long delays for quick questions.
Written Feedback Loops (40 Calendar Days): When sponsors submit complex technical documents (e.g., bench testing protocols, human factors evaluation plans, or animal study designs), the TAP Advisor coordinates internal CDRH subject-matter expert reviews and returns consolidated written feedback within 40 calendar days.
Ad-Hoc Touchpoints: Between formal meetings, sponsors can communicate directly with their TAP Advisor via email or short check-in calls to clarify regulatory feedback or discuss minor protocol adjustments.
Pre-Submission Alignment Meetings: Prior to filing formal IDEs or marketing applications, the TAP Advisor facilitates pre-filing alignment sessions with the full FDA review team to ensure all agreed-upon endpoints and testing evidence are complete.

Standard Q-Sub vs. TAP Response Time Comparison

Timeline Comparison: Requesting FDA Feedback on Clinical Trial Protocol Revisions

Standard Q-Sub Track:
Day 0: Submit Q-Sub ──► Day 15: Acceptance Review ──► Day 60-75: Formal Meeting ──► Day 90: Minutes Finalized
Total Duration: 75 to 90 Days

TAP Advisory Track:
Day 0: Email TAP Advisor ──► Day 14: Informal Teleconference ──► Day 40: Written Feedback Summary
Total Duration: 14 to 40 Days (Saved: 50+ Days per iteration)

Payor and Patient Engagement Under TAP: Bridging FDA Clearance with CMS Coverage

One of the most persistent hurdles for innovative medical device companies is the "Valley of Death" between obtaining FDA clearance or approval and securing reimbursement coverage from commercial payors and Medicare. Historically, a medical device could win FDA clearance based on safety and substantial equivalence, only to stall commercially for 2 to 5 years while waiting for CMS coding, coverage determinations, and payment assignments.

TAP addresses this disconnect by integrating payor and patient engagement directly into pre-market regulatory planning.

Multi-Stakeholder Engagement Architecture in FDA TAP

                    ┌────────────────────────────────────────┐
                    │      FDA CDRH Review Leadership        │
                    └───────────────────┬────────────────────┘
                                        │
                                        ▼
    ┌───────────────────────────────────────────────────────────────────────┐
    │                       Dedicated TAP Advisor                           │
    └───────┬───────────────────────────┬───────────────────────────┬───────┘
            │                           │                           │
            ▼                           ▼                           ▼
┌───────────────────────┐   ┌───────────────────────┐   ┌───────────────────────┐
│     Payor & CMS       │   │  Clinical Specialty   │   │   Patient Advocacy    │
│    Reimbursement      │   │       Societies       │   │     Organizations     │
├───────────────────────┤   ├───────────────────────┤   ├───────────────────────┤
│ • CMS Coverage Team   │   │ • Clinical Guideline  │   │ • Patient-Reported    │
│ • Private Health Plans│   │   Committee Chairs    │   │   Outcomes (PROs)     │
│ • AMA CPT Coding      │   │ • Key Opinion Leaders │   │ • Human Factors &     │
│ • Commercial Insurers │   │ • Trial Investigators │   │   Usability Feedback  │
└───────────────────────┘   └───────────────────────┘   └───────────────────────┘

1. Proactive Payor Alignment (CMS & Commercial Insurers)

Through TAP, FDA coordinates voluntary, confidential discussions between the device sponsor and healthcare payors, including Medicare medical directors, private health plans, and health technology assessment (HTA) bodies. Payors provide feedback on:

Clinical Endpoint Selection: Identifying reimbursement-relevant clinical endpoints (e.g., reduction in 90-day hospital readmissions, total cost of care reduction, or long-term functional improvement) that go beyond FDA’s safety and effectiveness baseline.
Comparator Arm Design: Ensuring trial comparator arms satisfy payor demands for active-control comparison against current standard-of-care therapies.
Health Economics & Outcomes Research (HEOR): Advising sponsors on collecting health economics data concurrently during pivotal clinical trials, preventing the need for post-market coverage studies.

This payor alignment under TAP is no longer optional or cosmetic — since April 2026 it has become a gating requirement for Medicare coverage. On April 23, 2026, CMS and FDA jointly announced the CMS-FDA RAPID Coverage Pathway, which compresses the gap between FDA market authorization and a Medicare national coverage determination to as little as 60 days for eligible Class II and Class III Breakthrough devices. Critically, a Class II Breakthrough device must be enrolled in TAP to qualify for RAPID — making TAP participation the on-ramp to the current accelerated-coverage route. RAPID replaces CMS's earlier Transitional Coverage for Emerging Technologies (TCET) pathway, which CMS is pausing for new candidates as RAPID takes effect.

2. CPT Coding, HCPCS Level II, and Payment Assignment Strategy

Securing a dedicated CPT Category I code or HCPCS Level II code is often as complex as passing FDA review. Through TAP payor sessions, sponsors gain early visibility into:

AMA CPT Editorial Panel Requirements: Determining whether clinical trial data will satisfy the American Medical Association’s criteria for a Category I CPT code (e.g., widespread clinical utilization and peer-reviewed literature).
HCPCS Level II Device Pass-Through Status: Evaluating Medicare pass-through eligibility for outpatient hospital procedures under the Hospital Outpatient Prospective Payment System (OPPS).
New Technology Add-On Payment (NTAP): Assessing whether inpatient hospital technologies meet the CMS substantial clinical improvement criterion for NTAP add-on reimbursement.

3. Comparing TAP Payor Track vs. FDA Payor Communication Taskforce (PCT)

Sponsors often ask how TAP payor alignment differs from the historical FDA Payor Communication Taskforce (PCT). The table below highlights key operational differences:

Program Feature	FDA TAP Payor Track	Historical Payor Communication Taskforce (PCT)
Initiation Trigger	Integrated directly into TAP Advisor onboarding	Standalone sponsor request submitted with a Q-Sub
Payor Participation Scope	CMS, commercial health plan medical directors, and HTA reviewers	Primarily CMS coverage directors and selected regional MACs
Meeting Turnaround	Coordinated within 30 to 45 days by TAP Advisor	Capped by formal 60-to-75-day Q-Sub meeting window
Scope of Discussion	Dual FDA regulatory safety/efficacy + payor reimbursement endpoints	Focused strictly on Medicare coverage requirements
Follow-up Continuity	Ongoing check-ins throughout pivotal trial protocol execution	Transactional single-meeting interaction

4. Clinical Specialty Society & KOL Engagement

TAP Advisors assist sponsors in identifying and engaging key opinion leaders (KOLs) from relevant medical specialty societies (e.g., American College of Cardiology, American Academy of Orthopaedic Surgeons). Specialty societies provide early input on:

Practical clinical workflow integration and usability.
Physician training and credentialing requirements.
Clinical practice guideline inclusion pathways.

5. Patient Advocacy & Patient-Centered Clinical Outcomes

TAP incorporates patient preference information (PPI) and patient-reported outcomes (PROs) into trial design. By engaging patient advocacy groups early, sponsors ensure clinical protocols evaluate endpoints that matter directly to patients (e.g., pain reduction, mobility retention, daily living independence), which enhances trial recruitment, retention, and FDA risk-benefit determinations.

Real-World Case Scenarios: How Device Sponsors Deploy TAP

To illustrate how TAP operates across distinct medical technology categories, consider three practical deployment scenarios:

Scenario A: Next-Generation Transcatheter Heart Valve (OHT2 / Cardiovascular)

Challenge: A medtech startup developed an innovative transcatheter mitral valve replacement (TMVR) system granted Breakthrough Designation. The team faced complex finite element analysis (FEA) fatigue testing requirements and uncertainty around pivotal trial primary endpoints.
TAP Deployment: Enrolled in TAP immediately post-Breakthrough grant. Used 14-day teleconferences to align bench-testing protocols with FDA biomechanics experts. Simultaneously engaged CMS and private payor representatives in TAP sessions to refine pivotal trial secondary endpoints—adding a 12-month heart failure hospitalization rate reduction endpoint requested by payors.
Outcome: Pivotal IDE approved on first submission; secured immediate CMS coverage under Coverage with Evidence Development (CED) upon PMA approval without a multi-year coverage gap.

Scenario B: AI-Driven Neuro-Rehabilitation Robotics (OHT4 / Neurological)

Challenge: An AI software and robotic exoskeleton developer targeted upper-limb stroke recovery. The team needed alignment on software change control protocols and human factors validation.
TAP Deployment: Utilized TAP 40-day written feedback loops to review Software Bill of Materials (SBOM) cybersecurity plans and human factors formative testing protocols. Held TAP payor meetings with major commercial health insurers to evaluate outpatient rehabilitation CPT coding requirements.
Outcome: Completed human factors validation on first attempt without FDA deficiency letters; established a clear pathway for Category I CPT code application post-clearance.

Scenario C: Rapid Point-of-Care Oncology IVD Assay (OHT7 / In Vitro Diagnostics)

Challenge: A diagnostic company designed a rapid liquid-biopsy assay for early lung cancer detection. Clinical trial design required establishing clinical performance across diverse patient demographics.
TAP Deployment: Leveraged TAP Advisor touchpoints to review clinical sample panel sizes and analytical reactivity protocols. Engaged patient advocacy organizations via TAP to refine patient-consent workflows and sample collection procedures.
Outcome: Accelerated IDE clinical trial enrollment by 40% through patient-centric trial protocol adjustments; achieved De Novo grant 5 months ahead of projected schedule.

TAP Teleconference Briefing Dossier: Preparation and Agenda Template

To maximize productivity during a 14-day TAP teleconference, regulatory teams should compile a streamlined briefing dossier. Unlike 100-page Q-Sub packages, a TAP teleconference dossier should be limited to 5 to 12 targeted pages.

Standard TAP Teleconference Agenda (30 to 45 Minutes)

Introduction and Development Update (5 Minutes): TAP Advisor and sponsor review target meeting objectives and confirm participants.
Technical / Clinical Question Presentation (10 Minutes): Sponsor summarizes the specific question (e.g., animal model selection or bench testing sample size) and presents proposed approach.
FDA TAP Advisor & Subject Matter Expert Feedback (15 Minutes): FDA experts provide informal technical feedback, identify potential review pitfalls, and discuss alternative testing approaches.
Payor / Stakeholder Perspective (5 Minutes): If payors or clinical KOLs are present, discuss clinical utility and reimbursement implications.
Action Items and Next Touchpoints (5 Minutes): Confirm agreed-upon path forward and set target timeframe for next informal touchpoint.

Essential Dossier Components

Executive Device Overview: 1-page summary of device technology, indication for use, and Breakthrough Designation status.
Specific Discussion Questions: 2 to 3 sharply focused questions with clear sponsor positions.
Supporting Data Summary: Condensed summary tables or figures illustrating bench, analytical, or preliminary pre-clinical results.
Proposed Protocol / Test Method: Key draft testing protocol or clinical endpoint definition for FDA feedback.

Key Risk Boundaries and Limitations: What TAP Advisors Cannot Do

While TAP provides unprecedented access and speed, sponsors must maintain realistic expectations regarding program boundaries. Regulatory affairs leaders should note the following limitations:

TAP Advisors Do Not Grant Approvals: A TAP Advisor is an advisory strategist, not a primary lead reviewer. Final marketing clearance or approval decisions remain under the statutory authority of the CDRH review division and Office Director.
TAP Is Not a Shortcut Around Safety Data: TAP accelerates dialogue, not data requirements. Bench testing, biocompatibility, software validation, and clinical evidence standards remain 100% intact.
Formal Submissions Are Still Mandatory: Informal agreement reached during a 14-day TAP teleconference must still be formally documented in subsequent IDE or premarket filings.
Payor Agreement Is Non-Binding: Payor participation in TAP is advisory. A private health plan representative participating in a TAP session provides informal feedback; formal coverage determinations remain subject to standard commercial health plan HTA evaluations post-clearance.

Step-by-Step TAP Application and Strategy: When to Request Enrollment and How to Prepare

Enrolling in TAP requires a clear strategic plan. Because annual enrollment spots are limited by MDUFA V capacity caps, sponsors must request enrollment at the optimal strategic window.

Sponsor Roadmap: Maximizing Value from TAP Enrollment

Step 1: Secure Breakthrough Designation
   └─► File formal Breakthrough Designation request under 21 USC 360e-3
   
Step 2: Submit TAP Enrollment Request
   └─► Request TAP enrollment immediately upon Breakthrough grant (prior to IDE filing)
   
Step 3: Initial TAP Advisor Onboarding
   └─► Conduct kick-off teleconference within 14 days; map TPLC engagement goals
   
Step 4: Multi-Stakeholder Pre-Clinical Alignment
   └─► Convene FDA, CMS payors, and clinical KOLs to review pivotal trial protocol
   
Step 5: Rapid Protocol Iteration
   └─► Utilize 14-day advisor calls & 40-day written reviews to finalize IDE/PMA protocol

Step 1: Secure Breakthrough Device Designation

Before applying to TAP, your device must have an active Breakthrough Device Designation granted by FDA. If your device meets the Breakthrough criteria (provides more effective treatment/diagnosis for life-threatening or irreversibly debilitating conditions, and meets at least one Breakthrough criterion), file your Breakthrough request early.

Step 2: Submit TAP Enrollment Request Promptly

Upon receiving your Breakthrough Designation grant letter, submit your TAP enrollment request immediately. The request is submitted as an amendment to your Breakthrough Designation Q-Submission (Q-Sub) tracking number. Do not wait until your clinical trial protocol is finalized; enrolling early yields the highest return by allowing TAP Advisors to shape protocol development.

Step 3: Prepare the TAP Onboarding Package

Your TAP enrollment request should contain a concise (5 to 10 page) onboarding summary outlining:

Device description, mechanism of action, and intended use.
Current development stage and target milestone dates (e.g., non-clinical testing completion, IDE filing, pivotal trial launch).
Key regulatory and reimbursement objectives for TAP engagement (e.g., clinical endpoint validation, CMS payor feedback, animal model acceptability).
Specific OHT review branch and target product code.

Step 4: Execute the Multi-Stakeholder Consultation Plan

Once enrolled, work with your TAP Advisor to map out a 12-month consultation schedule. Schedule informal 14-day teleconferences prior to initiating major testing blocks (e.g., biocompatibility testing plans, software validation strategies, pivotal trial sample size calculations). Request payor engagement sessions 6 to 9 months before finalizing your pivotal clinical trial protocol.

Frequently Asked Questions About FDA TAP Pilot Program (FAQ)

Does TAP cost extra user fees under MDUFA V?

No. There are no additional user fees to enroll in or participate in the TAP Pilot Program. TAP is fully funded through the MDUFA V user fee agreement reauthorization negotiated between FDA CDRH and the medical device industry for FY 2023 through FY 2027.

Can a device enroll in TAP if it has already submitted an IDE or 510(k)?

No. TAP is restricted to devices in early-stage premarket development. If a sponsor has already submitted an Investigational Device Exemption (IDE) or filed a marketing submission (510(k), De Novo, or PMA), the device is ineligible for TAP enrollment. CDRH enforces this rule to ensure advisory resources are directed where early guidance can prevent downstream protocol redesigns.

How fast are TAP advisor meetings scheduled compared to traditional Pre-Submissions?

Informal teleconferences with your assigned TAP Advisor are scheduled within 14 calendar days of a sponsor request. Consolidated written feedback on technical protocols is provided within 40 calendar days. By comparison, standard Q-Submissions require 60 to 75 calendar days from submission receipt to meeting date.

Does TAP guarantee CMS coverage or NTAP approval for Breakthrough Devices?

No. Participation in TAP does not guarantee Medicare coverage or a positive National Coverage Determination (NCD). What it does is open the fastest current route to one: under the April 23, 2026 CMS-FDA RAPID Coverage Pathway, a Class II Breakthrough device must be enrolled in TAP to use RAPID, which can yield a Medicare coverage determination within roughly 60 days of FDA authorization. TAP also gives sponsors early, direct access to CMS coverage officers and private payors, so pivotal trials can capture payor-requested clinical endpoints and health-economic data up front rather than after clearance.

On the payment side, sponsors should also know that on April 10, 2026, CMS proposed (in the FY 2027 IPPS proposed rule) to repeal the alternative NTAP pathway that had allowed Breakthrough devices to receive New Technology Add-On Payments without demonstrating substantial clinical improvement. If finalized, that repeal would take effect in FY 2028 and would also affect OPPS device pass-through payments. NTAP is therefore a less reliable fallback than it was a year ago — which makes early TAP-driven coverage alignment more valuable, not less.

Conclusion & Strategic Recommendations

The FDA CDRH TAP Pilot Program represents a transformative opportunity for Breakthrough medical device developers to compress regulatory timelines, de-risk clinical trial investments, and solve reimbursement challenges concurrently. By replacing rigid statutory review clocks with continuous, concierge-level TAP Advisor touchpoints, sponsors can eliminate months of administrative waiting time.

Device developers holding or pursuing Breakthrough Designation should:

Apply to TAP immediately upon receiving Breakthrough Designation, before locking clinical trial protocols or filing IDEs.
Leverage TAP’s multi-stakeholder framework to engage CMS and commercial payors early, ensuring trial endpoints support both FDA marketing authorization and commercial reimbursement.
Utilize 14-day informal teleconferences to resolve technical, non-clinical, and software validation questions iteratively.

For further guidance on FDA expedited pathways and premarket strategy, explore our detailed analyses on FDA Breakthrough Device Designation, CMS Rapid Coverage Pathways, FDA STEP Program, and 510(k) Submission Execution.